| Public | NASDAQ:ONTY |
| Website | oncothyreon.com |
| Category | BioTech |
| Phone | (206) 801-2100 |
| Employees |
| TOTAL | $54.9M |
| VENTURE FUNDING TOTAL | $54.9M |
| Venture Round, 9/10 Cowen Group Iroquois Capital Dafna Capital Management Straus Partners Downsview Capital Heights Capital Management Hudson Bay Capital Management Ramius Advisors Ayer Capital Management Hartz Capital Kingsbrook Partners | $14.9M |
| Venture Round, 4/11 | $40M |
Oncothyreon Inc. (Oncothyreon) is a clinical-stage biopharmaceutical company. The Company focuses primarily on the development of therapeutic products for the treatment of cancer. Oncothyreon’s cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. The Company’s lead product candidate under clinical development is a vaccine it calls Stimuvax. Stimuvax incorporates a 25 amino acid sequence of the cancer antigen MUC1, in a liposomal formulation. Stimuvax is designed to induce an immune response to destroy cancer cells that express MUC1, a protein antigen widely expressed on many common cancers, such as lung cancer, breast cancer and colorectal cancer. Oncothyreon has granted an exclusive, worldwide license to Merck KGaA of Darmstadt, Germany (Merck KGaA), for the development, manufacture and commercialization of Stimuvax.
